Highlights Purple Biotech Ltd

Equities

PPBT

IL0007650166

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 07:54:27 06/06/2024 pm IST			5-day change	1st Jan Change
21.4 ^ILa	-3.17%		-22.46%	-32.92%

01/06	Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer	CI
25/04	Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer	01/06	CI
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25/04	CI
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14/03	CI
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03	CI
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03	CI
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27/02	CI
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	01/02	CI
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12	CI
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Purple Biotech Reports Potential Biomarker Data Support CM24?s Mechanism of Action	06/23/06	CI
Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer	03/23/03	CI
Purple Biotech Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients	11/23/11	CI
Purple Biotech Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	17/23/17	CI
Kitov Pharmaceuticals Holdings Ltd. Submits New Drug Application to FDA for KIT-302	01/17/01	CI
Kitov Pharmaceuticals Holdings Ltd. Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model	18/17/18	CI
Kitov Pharmaceuticals Holdings Ltd. Provides Updates on KIT-302 New Drug Application	27/17/27	CI
U.S. Food and Drug Administration Grants Kitov Pharmaceuticals Holdings Ltd for New Drug Application Filing Fee	03/17/03	CI
Kitov Pharmaceuticals Holdings Ltd. Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2016	28/17/28	CI
Kitov Pharmaceuticals Holdings Ltd Announces License Agreement for Kit-302 in South Korea	08/17/08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Purple Biotech Ltd

Equities

PPBT

IL0007650166

Highlights

Filters